BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GBI Research Release: $800 Billion: The Amount US Healthcare Industry "Wasted" in 2011


8/22/2012 12:12:30 PM

NEW YORK (GBI Research), 22 August 2012 - Avoidable care, incompetent hospital management and administrations scams accounted for an astonishing $800-$900 billion in unnecessary healthcare expenditure in the US last year, according to the latest findings of business intelligence experts GBI Research.

The new report* contrasts the astronomical figure with the total US government healthcare budget, which for 2012 stands at a comparable $1.1 trillion.

Hugely excessive waste across the nation’s healthcare system contributes significant to unnecessary treatment costs. Medical practitioners may prescribe branded products where cheaper generic alternatives may be issued for the same condition, while patients who miss scheduled pharmaceutical treatments can incur extra costs such as laboratory tests and physician visits.

Wastage can also occur when medications for patients with acute conditions are not delivered in time, rendering the treatment redundant and resulting in considerable damage to the patient.

The US spends the most in the world on healthcare – 17.9% of GDP in 2010 – and has been continually expanding, even during the global economic recession, as other developed countries such as the UK, Germany and Italy have been forced to reduce healthcare expenditure.

Thanks in part to President Obama’s Patient Protection and Affordable Care Act (PPACA), US government spending on healthcare is forecast to continue to increase in size, reaching $1.6 trillion by 2017.

* Pharmaceutical Pricing and Reimbursement - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making

This report provides a comprehensive overview of the healthcare system and pricing and reimbursement process in the US, top five countries of Europe (the UK, Germany, France, Spain and Italy), Japan, Australia and China, with a detailed analysis of the different regulatory mechanisms used in these countries.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@gbiresearch.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES